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The role of the highly-conserved ’DRY’ motif in the signaling of the CB1 cannabinoid 
receptor (CB1R) was investigated by introducing single, double and triple alanine 
mutations into this site of the receptor. We found that the CB1R-R3.50A mutant displays 
a partial decrease in its ability to activate heterotrimeric Go proteins (~80% of wild-type 
CB1R (CB1R-WT)). Moreover, this mutant showed an enhanced basal β-arrestin2 
recruitment. More strikingly, the double mutant CB1R-D3.49A/R3.50A was biased 
toward β-arrestins, as it gained a robustly increased β-arrestin1 and β-arrestin2 
recruitment ability compared to the wild-type receptor, while its G protein activation was 
decreased. In contrast, the double mutant CB1R-R3.50A/Y3.51A proved to be G protein-
biased, as it was practically unable to recruit β-arrestins in response to agonist stimulus, 
while still activating G proteins, although at a reduced level (~70% of CB1R-WT). 
Agonist-induced ERK1/2 activation of the CB1R mutants showed good correlation with 
their β-arrestin recruitment ability but not with their G protein activation or inhibition of 
cAMP accumulation. Our results suggest that G protein activation and β-arrestin binding 
of the CB1R are mediated by distinct receptor conformations and the conserved ‘DRY’ 
motif plays different roles in the stabilization of these conformations, thus mediating both 
G protein- and β-arrestin-mediated functions of CB1R. 
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Seven transmembrane receptors (7TMRs) constitute the largest family of plasma 
membrane receptors. Most of their intracellular effects are mediated via direct coupling to 
heterotrimeric G proteins. To understand the molecular details of 7TMR activation and G 
protein coupling, identification of key structural elements regulating these processes is 
critically important. Using mutational analyses as well as recent high resolution X-ray 
crystal structure data, such structural features have been extensively mapped 
(Venkatakrishnan et al. 2013). Among these, the conserved Asp-Arg-Tyr (DRY) motif, 
located at the beginning of the second intracellular loop (ICL2), seems to play a central 
role both in the activation and the G protein coupling of class A (rhodopsin-like) 7TMRs 
(Rasmussen et al. 2011). Nevertheless, the exact nature of this regulatory role is still not 
completely understood. For instance, although the Arg residue (R3.50) is suggested to 
directly interact with the G protein α subunit in the active 7TMR conformation, its non-
conservative mutations in many cases fail to impair G protein coupling of the receptor 
(Fanelli et al. 1999; Rhee et al. 2000; Rovati et al. 2007). Furthermore, Asp (D3.49) is 
believed to stabilize inactive receptor conformation by forming a salt-bridge with the 
neighboring R3.50 (Scheer et al. 1996; Scheer et al. 1997; Ballesteros et al. 1998; 
Ballesteros et al. 2001; Li et al. 2001), however, its mutations can also result in 
completely diverse phenotypes, depending on the investigated receptor (Rovati et al. 
2007). Therefore, the exact role of the DRY motif obviously shows receptor-specific 

























Besides G proteins, β-arrestins are also able to directly bind to the intracellular surface of 
an activated 7TMR, leading to the desensitization and internalization of the receptor 
(Shenoy and Lefkowitz 2011). Moreover, receptor-bound β-arrestins can also serve as a 
starting point for G protein-independent signaling pathways, such as the activation of the 
p42/44 mitogen-activated protein kinase (MAP kinase) cascade or Src kinases (Wei et al. 
2003; DeWire et al. 2007).  
Many data suggest that the β-arrestin-bound conformation of 7TMRs may differ from the 
one mediating their G protein activation, a fact being implicitly exploited by several 
functionally selective 7TMR ligands as well as by functionally selective 7TMR mutants, 
which are able to induce β-arrestin recruitment without affecting G protein coupling or 
vice versa (Reiter et al. 2012). However, in the lack of a high resolution crystal structure 
describing a 7TMR in its β-arrestin-bound form, relatively little is known about the 
receptor-arrestin binding interface. According to the prevailing idea, arrestins utilize two 
distinct sites to bind to 7TMRs, one of which is a ‘phosphorylation sensor’, recognizing 
Ser/Thr-phosphorylated C-terminus of the receptor (Gurevich and Benovic 1993; 
Gurevich and Gurevich 2006). The other site is a so-called ‘activation sensor’, which 
recognizes the active 7TMR conformation, independently of receptor phosphorylation 
(Gurevich and Gurevich 2006). The 7TMR elements constituting the docking site for the 
arrestin ‘activation sensor’ are less understood. The second intracellular loop (ICL2), 
beginning with the DRY motif, has been proposed to play such a role (Huttenrauch et al. 
2002; Marion et al. 2006). Furthermore, complementary roles for the DRY motif and 
receptor C-terminus in the regulation of β-arrestin binding have been described (Kim and 

























binding and subsequent constitutively desensitized phenotype of 7TMRs (Barak et al. 
2001; Wilbanks et al. 2002). Thus, the conserved DRY motif seems to be involved not 
only in G protein coupling, but also in β-arrestin binding of 7TMRs. 
The CB1 cannabinoid receptor (CB1R) belongs to the 7TMR superfamily. The signaling 
pathways originating from CB1R are mediated mainly via heterotrimeric Gi/o proteins, 
and include inhibition of cAMP production, activation of GIRK potassium channels, 
inhibition of Cav calcium channels, and activation of MAP kinase cascades (Turu and 
Hunyady 2010). Moreover, CB1R shows basal G protein activation and constitutive 
internalization under diverse cellular conditions (Leterrier et al. 2006; McDonald et al. 
2007; Turu et al. 2007). Like most other 7TMRs, CB1R also recruits β-arrestin following 
activation, which leads to the desensitization and internalization of the receptor 
(Kouznetsova et al. 2002; Daigle et al. 2008; Gyombolai et al. 2013). The binding 
between β-arrestins and CB1R is relatively weak, and the affinity of the receptor for β-
arrestin2 (β-arr2) is substantially higher than that for β-arrestin1 (β-arr1) (Gyombolai et 
al. 2013). Furthermore, β-arr1 recruitment of CB1R appears to be agonist-dependent 
(Laprairie et al., 2014; Flores-Otero et al., 2014). Interestingly, in addition to canonical G 
protein-mediated intracellular effects, recent data suggest the existence of β-arrestin-
mediated, G protein-independent signaling of CB1R, i.e. the p42/44 MAPK (ERK1/2) 
activation of the receptor seems to be at least partly mediated by β-arrestins (Ahn et al. 
2013a; Mahavadi et al. 2014). 
Via these cellular events, CB1R is involved in the regulation of many important 
physiological and pathophysiological processes, such as memory, learning, pain 

























Moreover, several natural and synthetic cannabinoid ligands are known to stabilize 
distinct active CB1R conformations, i.e. prove to be functionally selective (Glass and 
Northup 1999; Mukhopadhyay and Howlett 2001; Ahn et al. 2013a). Thus, investigation 
of the structural elements responsible for G protein- and β-arrestin-mediated CB1R 
functions has a major physiological and pharmacological impact. Accordingly, a number 
of studies have aimed to identify such regulatory motifs of CB1R. A detailed 
computational model based on the crystal structure of the β2-adrenergic receptor-Gαs 
complex, combined with mutational data, suggested that distinct residues in the ICL2 and 
ICL3 regions of the CB1R may be involved in the stabilization of the active, Gαi-coupled 
receptor conformation (Shim et al. 2013). Two other recent studies analyzed the role of 
several intramolecular salt-bridges, which may stabilize inactive, partially active and 
fully active CB1R conformations (Ahn et al. 2013b; Scott et al. 2013). According to this 
model, D3.49 and R3.50 residues form salt-bridges with K4.41 and D6.30, respectively, 
which (together with a D2.63+K3.28 salt-bridge) may keep the receptor in a partially 
active conformation under basal conditions.  
Less is known about the structural features governing the β-arrestin binding of CB1R. The 
C-terminal Ser/Thr phosphorylation of the receptor seems to play a role, since alanine 
mutations of these residues impaired agonist-induced β-arrestin recruitment and 
subsequent internalization of CB1R (Daigle et al. 2008). 
Although the above studies clearly provide important insights into the molecular details 
of CB1R function, none of them assessed the role of the DRY motif in CB1R function 
directly, i.e. through mutational analysis. More importantly, none of the available studies 
























terminus. Therefore, our goal was to analyze the role of the conserved DRY sequence in 
the G protein activation and β-arrestin binding of CB1R. We introduced single, double 
and triple alanine mutations into this site of CB1R and applied functional assays directly 
measuring G protein activation, β-arr2 recruitment and intracellular signaling of wild-
type and mutant CB1R variants. 
 
2. Materials and Methods 
 
2.1. Materials  
 
The cDNA of the rat vascular CB1R was provided by Zsolt Lenkei (Centre National de la 
Recherche Scientificue, Paris). cDNAs of human β1 and γ11 G protein subunits were 
purchased from the Missouri S&T cDNA Resource Center (Rolla, MO). β-arr2-eGFP 
cDNA was kindly provided by Dr. Marc G. Caron (Duke University, Durham, NC). 
Molecular biology enzymes were obtained from Fermentas (Vilnius, Lithuania) and 
Stratagene (La Jolla, CA). Fetal bovine serum (FBS), OptiMEM, Lipofectamine 2000, 
and PBS-EDTA were from Invitrogen (Carlsbad, CA). CHO-K1 and HeLa cell lines were 
obtained from ATCC (American Type Culture Collection, Manassas, VA). 
Coelenterazine h was from Regis Technologies (Morton Grove, IL). WIN55,212-2, 2-
arachydonoylglycerol and AM251 were from Tocris (Bristol, UK). Cell culture dishes 
and plates for BRET measurements were from Greiner (Kremsmunster, Austria). Anti-

























from Cell Signaling Technology Inc. (Beverly, MA). Unless otherwise stated, all other 
chemicals and reagents were from Sigma (St. Louis, MO). 
 
2.2. Plasmid constructs and site-directed mutagenesis 
 
The mVenus-tagged rat CB1R (CB1R-mVenus) was created by exchanging the sequence 
of eYFP in CB1R-eYFP (kindly provided by Zsolt Lenkei (Centre National de la 
Recherche Scientificue, Paris)) to the sequence of mVenus using AgeI and NotI 
restriction enzymes. αo-Rluc and YFP-β1 constructs were created from αoA-CFP (kindly 
provided by Dr. N. Gautam (Azpiazu and Gautam 2004)), and β1, respectively, as 
described previously (Turu et al. 2007). β-arr2-Rluc was constructed as described 
previously (Turu et al. 2006). Plasma membrane-targeted mVenus (MP-mVenus) was 
constructed as described previously (Varnai et al. 2007). Plasma membrane-targeted 
super Renilla luciferase (MP-Sluc) was generated from MP-mVenus by replacing the 
mVenus coding sequence with the cDNA of super Renilla luciferase (Woo and von 
Arnim, 2008).The EPAC-based BRET sensor was constructed as described previously 
(Erdelyi et al. 2014). Mutations in the DRY motif of CB1R or CB1R-mVenus were 
inserted by the QuikChange® site-directed mutagenesis kit (Stratagene, La Jolla, CA) 
according to manufacturer’s suggestions. Sequences of all constructs were verified using 
automated DNA sequencing.  
 


























CHO or HeLa cells (passage numbers 5 to 15) were maintained in Ham’s F12 or DMEM, 
respectively, supplemented with 10% FBS, (Invitrogen, Carlsbad, CA), 100 μg/ml 
streptomycin, and 100 IU/ml penicillin in 5% CO2 at 37 °C. For confocal microscopy 
experiments, cells were grown on glass coverslips in 6-well plates and transfected with 
the indicated constructs using Lipofectamine 2000 in OptiMEM following the 
manufacturer’s instructions. For BRET and Western blot experiments, cells were grown 
on 6-well plates and transfected with the indicated constructs using Lipofectamine 2000 
in OptiMEM following the manufacturer’s instructions.  
 
2.4. Bioluminescence resonance energy transfer (BRET) measurements 
 
A detailed description of the BRET measurements applied here can be found in 
Supplementary Methods.  
 
2.5. Confocal laser-scanning microscopy 
 
Cells were grown on glass coverslips and transfected with the appropriate constructs 
(using 2 µg/well CB1R-mVenus or 0.5 µg/well β-arr2-GFP and 2 µg/well CB1R). Cells 
were analyzed 22-26 hours later in a modified Krebs-Ringer buffer (see above), using a 
Zeiss LSM 710 confocal laser scanning microscope. 
 















A detailed description of the Western blot measurements applied here can be found in 
Supplementary Methods.  
 
2.7. Data analysis 
 
Dose-response curves for G protein, β-arrestin and EPAC BRET measurements were 
fitted and statistically compared using built-in algorithms of GraphPad Prism 4.03 
(GraphPad Software Inc, San Diego, CA). Equimolar comparison was carried out by 
plotting the points of G protein and β-arr2 BRET dose-response curves for vehicle, -8.0 
(only by WIN55), -7.5, -7.0, -6.5, -6.0, -5.5 and -5.0 (only by 2-AG) log[WIN55] or 
log[2-AG] (M) treatments of the same receptor against each other. Equiactive comparison 




























1max,logβ , (Rajagopal et al. 2011), where Emax,1, 
EC50,1, Emax,2 and EC50,2 are Emax and EC50 values from G protein and β-arrestin BRET 
dose-response curves, respectively, using CB1R-WT as reference receptor. Quantified 
Western-blot data were evaluated with two-way ANOVA combined with Holm-Sidak’s 
post-hoc test, using the software SigmaStat for Windows 3.5 (Systat Software Inc., 








































To investigate whether any of the mutations inserted into the DRY motif of CB1R affects 
the proper plasma membrane localization of the receptor, CHO cells expressing mVenus-
tagged CB1R variants were analyzed using confocal microscopy. In resting cells, CB1R-
mVenus is localized both at the plasma membrane and in intracellular vesicles, consistent 
with the constitutive internalization of CB1R (Fig. 1A). Importantly, D3.49A mutation 
strongly impaired plasma membrane localization of CB1R, with most of the receptors 
being retained in the endoplasmic reticulum of the cells (CB1R-D3.49A-mVenus (CB1R-
ARY-mVenus) and CB1R-D3.49A/Y3.51A-mVenus (CB1R-ARA-mVenus), Fig. 1B and 
F, respectively). Interestingly, this effect of the D3.49A mutation was reversed by co-
mutation of R3.50, as the double mutant CB1R-D3.49A/R3.50A (CB1R-AAY) and the 
triple mutant CB1R-D3.49A/R3.50A/Y3.51A (CB1R-AAA) both showed proper plasma 
membrane localization (Fig. 1G and H, respectively). The other three mutants, i.e. CB1R-
R3.50A (CB1R-DAY), CB1R-Y3.51A (CB1R-DRA) and CB1R-R3.50A/Y3.51A (CB1R-
DAA) displayed a cellular distribution roughly similar to that of the wild-type receptor 
(Fig 1C, D and E, respectively).  
Since analysis of confocal images is in many cases not sensitive enough to detect fine 
changes in receptor distribution, we also applied a more quantifiable approach here, i.e. 
we measured the BRET interaction levels between CB1R-mVenus and plasma 
membrane-targeted Sluc protein. The fraction of the receptors residing on the plasma 
membrane of non-stimulated cells (PM/total receptor BRET) was found to be similar in 
cells expressing CB1R-WT, CB1R-AAY or CB1R-AAA, whereas  CB1R-DAY, CB1R-

























Furthermore, in accordance with confocal images, the plasma membrane localization of 
CB1R-ARY and CB1R-ARA was shown to be almost completely diminished (Fig. 1I). 
Since the plasma membrane localization of the CB1R-ARY and CB1R-ARA mutants was 
severely disrupted, these two mutants were not characterized in the subsequent studies. 
 
3.2. R3.50A mutation partially affects CB1R function 
 
R3.50 is the most conserved residue within the DRY motif, therefore we first checked the 
functionality of the CB1R-DAY mutant. The G protein activation of the receptor was 
directly monitored by measuring BRET changes between heterotrimeric Go protein 
subunits (αo-Rluc and YFP-β1γ11) (Turu et al. 2007), co-expressed with wild-type or 
mutant CB1R. In control experiments measuring BRET donor and acceptor partner 
expression directly (i.e. through luminescence and fluorescence counts, respectively) no 
significant changes were detected between these values when tested with the different 
CB1R mutants, suggesting that the observed changes in BRET were not due to alterations 
in BRET partner stoichiometry. This applies for all of the Go BRET and β-arrestin BRET 
experiments presented in this study (data not shown). Dose-response curves performed 
with the synthetic CB1R agonist WIN55,212-2 (WIN55) or with the endocannabinoid 2-
arachydonoylglycerol (2-AG) showed that the CB1R-DAY mutant is impaired, but not 
completely disrupted in its ability to activate Go proteins. Moreover, CB1R-DAY shows a 
basal G protein activation similar to that of CB1R-WT (Fig. 2A and B). The EC50 value of 
CB1R-DAY was also similar to that of CB1R-WT, indicating that the G protein binding of 
CB1R is not affected by the R3.50A mutation (Table 1). 
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Next, the β-arr2 recruitment of CB1R-DAY was investigated. GFP-tagged β-arr2 (β-arr2-
GFP) was co-expressed with CB1R-DAY in CHO cells, and its distribution was analyzed 
under confocal microscopy. Interestingly, we found that in cells co-expressing β-arr2-
GFP and CB1R-DAY, β-arr2-GFP was recruited to the plasma membrane in punctuate 
structures already in resting cells, indicating an increased basal β-arr2 recruitment of 
CB1R-DAY (Fig. 2E and G). Such basal recruitment of β-arr2-GFP could not be 
observed with CB1R-WT (Fig. 2C).  This basal recruitment of β-arr2 was the 
consequence of a partially active receptor conformation, since treatment with the CB1R 
inverse agonist AM251 (10 µM, 10 min) resulted in the disappearance of most of the β-
























After addition of the CB1R agonist WIN55 (1 µM, 10 min) further translocation of β-
arr2-GFP to the plasma membrane could be observed in case of CB1R-DAY, however, 
this did not reach the level of β-arr2-GFP recruitment of the CB1R-WT (Fig. 2D and F). 
To evaluate β-arr2 recruitment in a more quantitative manner, translocation of β-arr2 to 
the receptors was followed by monitoring BRET changes between β-arr2-Rluc and 
plasma membrane targeted mVenus (MP-mVenus). With this assay, β-arr2 recruitment to 
the investigated receptor can be monitored without tagging the receptor itself directly, 
which is advantageous because the detected BRET changes are not influenced by 
possible orientational changes resulting from the introduced receptor mutations. 
Furthermore, BRET signal in this assay is only affected via receptors residing on the 
plasma membrane, i.e. BRET ratios are not disturbed by intracellular receptor population. 
Dose-response curves performed with WIN55 in this β-arr2 BRET assay were in good 
accordance with the data obtained by confocal microscopy, i.e. the increased basal β-arr2 
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recruitment of CB1R-DAY, as well as a lower β-arr2 recruitment in response to agonist 
stimulus were detectable (Fig. 2I). Similar results were obtained with the 

























3.3. Y3.51A mutation increases constitutive activity of CB1R 
 
Among the three residues of the DRY motif, Y3.51 is the least conserved, and relatively 
little is known about its role in 7TMR signaling. To obtain data about its role in CB1R 
regulation, we tested the CB1R-DRA mutant under our experimental settings. 
Interestingly, although the maximal G protein activation of this mutant was only 
marginally impaired (i.e. a significant change in Emax was only detectable upon 2-AG 
stimuli), the G protein BRET dose-response analysis indicated an elevated basal G 
protein activation for this mutant (Fig. 3A and B, Table 1). Confocal microscopy analysis 
showed that, similarly to the CB1R-DAY mutant, basal β-arr2 recruitment of CB1R-DRA 
occurs (Fig. 3C and E), which could be reversed by inverse agonist treatment (Fig. 3F). 
Agonist-induced β-arr2-GFP translocation to the plasma membrane was very weak (Fig. 
3D). β-arr2 BRET analysis was in accordance with confocal data, namely, dose-response 
curve showed elevated basal β-arr2 recruitment together with a significantly impaired 
agonist-induced β-arr2 translocation (Fig. 3G and H). 
 




Next, we investigated the signaling properties of the double mutant CB1R-AAY. The G 
protein activation was monitored by the BRET assay described above. Dose-response 
curves carried out with WIN55 or 2-AG showed that the CB1R-AAY mutant has 
impaired Go activation ability (Fig. 4A and B), which is reflected both in the Emax and the 
pEC50 values of these interactions (Table 1). Moreover, basal G protein activation of this 
























The β-arr2 recruitment of CB1R-AAY was investigated also by β-arr2-GFP co-expression 
under confocal microscope. We found that, similarly to CB1R-DAY and CB1R-DRA, 
CB1R-AAY recruited β-arr2-GFP to the plasma membrane in non-stimulated cells (Fig. 
4C and E). The basal β-arr2 recruitment could be reversed with inverse agonist AM251 
treatment (Fig. 4F). Upon addition of WIN55, a very robust translocation of β-arr2-GFP 
to the plasma membrane was observed, with practically no β-arr2-GFP remaining in the 
cytoplasm (Fig. 4D). We further evaluated the β-arr2 recruitment of CB1R-AAY with the 
BRET-based method described above. WIN55 and 2-AG dose-response curves showed 
that, in addition to the increased basal β-arr2 recruitment of CB1R-AAY, this mutant 
gained a substantially increased ability to recruit β-arr2 upon agonist stimulus, as shown 
by the significant left- and upward shift of the curves (Fig. 4G and H, Table 1). These 
results suggest that the signaling of this mutant is shifted from G protein activation 
towards β-arr2 recruitment, and therefore CB1R-AAY can be considered as a β-arr2-
biased mutant. 
The characteristics of the triple mutant CB1R-AAA) were very similar to that of CB1R-
AAY, i.e. a decrease in basal and agonist-induced G protein activation, as well as an 


























3.5. The CB1R-DAA mutant is G protein-biased 
 
In the next set of experiments, the functional characteristics of the CB1R-DAA double 
mutant receptor were analyzed. Dose-response curves obtained by Go protein BRET 
assay showed that the CB1R-DAA mutant can activate G proteins at a lowered level 
(~75% of CB1R-WT), although pEC50 values as well as basal G protein activation 
remained unaffected (Fig. 5A and B, Table 1). 
Confocal microscopy analysis of β-arr2-GFP co-expressed with CB1R-DAA showed that 
this mutant, similarly to the CB1R-DAY, CB1R-DRA and CB1R-AAY mutants, recruited 
β-arr2-GFP to the plasma membrane under control conditions (Fig. 5C and E), and this 
was reversed by AM251 treatment (Fig. 5F). Interestingly, no further translocation of β-
arr2-GFP could be detected in these cells upon addition of the CB1R agonist WIN55 (Fig. 
5C). These results were strengthened by β-arr2 BRET measurements, showing a basal β-
arr2 recruitment for CB1R-DAA, which, however, cannot be enhanced by WIN55 or 2-
AG treatment (Fig. 5G and H). These results suggest that, in contrast to CB1R-AAY, the 
signaling of CB1R-DAA is shifted from β-arr2 recruitment towards G protein activation, 
and therefore CB1R-DAA can be considered as a G protein-biased mutant. 
 
3.6. β-arrestin1 recruitment of CB1R-AAY mutant is robustly enhanced 
 
In our previous study we could not detect significant β-arr1 coupling to the CB1R upon 
WIN55 stimulus, however, others have suggested that CB1R dependent β-arr1 
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recruitment can be present and may regulate ERK1/2 activation of CB1R (Laprairie et al., 
2014; Flores-Otero et al., 2014). To test whether DRY mutations of CB1R affect the 
recruitment of β-arr1, we applied the same BRET based approach as above, i.e. the 
plasma membrane translocation of β-arr1-Rluc was monitored, and dose-response curves 
were performed using WIN55 and 2-AG as agonists. Our results show that agonist-
induced β-arr1 recruitment is very low in cells expressing CB1R-WT, i.e. a significant 
increase could only be detected upon 2-AG treatment, whereas the changes obtained with 
WIN55 proved to be non-significant. Interestingly, the CB1R-AAY mutant displayed a 
robustly enhanced ability to recruit β-arr1, both upon WIN55 and 2-AG stimuli. All of 
the other three mutants (i.e. CB1R-DAY, CB1R-DRA and CB1R-DAA) produced non-

























3.7. Detailed data analysis strengthens biased signaling of DRY mutant CB1Rs  
 
The above results suggest that distinct mutations in the conserved DRY motif of the 
CB1R can differentially affect G protein activation and β-arr2 recruitment of the receptor. 
To assess this receptor bias in an exact manner, two different methods, proposed by 
Rajagopal et al. (Rajagopal et al. 2011), were applied to analyze data. First, ‘equimolar 
comparison’ was carried out, where G protein and β-arr2 responses elicited by the same 
ligand concentrations are plotted against each other. In the case of the ‘reference 
receptor’, i.e. CB1R-WT, this analysis yields a roughly hyperbolic shape with both 
WIN55 and 2-AG (Fig. 7A and B, respectively, black circles), reflecting the difference in 

























AAY are substantially shifted left- and upwards on these graphs, representing bias 
towards β-arr2 recruitment (Fig. 7A and B, white triangles). Furthermore, the points for 
CB1R-DAA are arranged along a horizontal line, demonstrating the bias of this receptor 
towards G protein activation (Fig. 7A and B, grey squares). The other method was 
‘equiactive comparison’, where the signaling of each receptor is characterized by a bias 
factor (β), based on the EC50 and Emax values from G protein and β-arr2 dose-response 
curves (Rajagopal et al. 2011). In case of the reference receptor (CB1R-WT), this bias 
factor is by definition 0. In the case of CB1R-DAA, the β values were 1.42 or 1.61 (for 
WIN55 or 2-AG stimuli, respectively), whereas the same values for CB1R-AAY were -
1.54 or -1.42, representing more than 10-fold bias of these two mutants towards G protein 
activation and β-arr2 recruitment, respectively (Fig. 7C). 
Taken together, our detailed bias analysis indicated that CB1R-AAY and CB1R-DAA can 
be considered as β-arrestin-biased and G protein-biased mutants, respectively. 
 
3.8. Functional assays reflect biased intracellular signaling of CB1R-AAY and CB1R-
DAA 
 
Next, we wanted to assess whether the differences seen at the level of receptor-effector 
protein coupling are reflected in more distal intracellular signaling events initiated by 
CB1R activation. First, Gi/o protein-mediated signaling was assessed by measuring 
inhibition of forskolin-induced cAMP accumulation under basal and CB1R-stimulated 
conditions, using an EPAC-based intramolecular BRET-sensor (Erdelyi et al. 2014). Our 
























conditions, and this is substantially and dose-dependently enhanced upon treatment with 
WIN55 (Fig. 8A). Importantly, WIN55-induced cAMP inhibition of the G protein-biased 
mutant CB1R-DAA was lower but still present, whereas CB1R-AAY, in accordance with 
its bias towards β-arr2, failed to induce the inhibition of cAMP accumulation in response 
to agonist stimulus (Fig. 8A). 
Recent data suggest that CB1R-induced p42/44 MAP kinase (ERK1/2) activation, which 
was formerly suggested to occur via G protein-dependent pathways (Galve-Roperh et al. 
2002; Davis et al. 2003; Dalton and Howlett 2012), is also mediated by β-arrestins (Ahn 
et al. 2013a; Mahavadi et al. 2014). Therefore, we aimed to study how the ERK1/2 
responses correlate with the G protein activation and/or β-arrestin recruitment of the 
biased CB1R mutants. Western blot experiments carried out with cells expressing CB1R-
WT showed a robust increase in the amount of phosphorylated ERK1/2 (pERK1/2) after 
5 min treatment with WIN55 (1 µM). Moreover, lower but sustained pERK1/2 levels 
were also detectable after 20 min WIN55 treatment (Fig. 7B and C). Interestingly, we 
found that the β-arr2-biased CB1R-AAY elicited pERK1/2 responses similar to CB1R-
WT, both at 5 and 20 min stimulation, whereas the G protein-biased CB1R-DAA 
produced significantly lower pERK1/2 responses than the wild-type receptor (Fig. 7B and 
C). Thus, ERK1/2 activation of the biased DRY mutants correlated well with their β-arr2 




























In this study, we evaluated the role of the conserved DRY motif in the function of the 
CB1R. Our goal was to assess its role in mediating basal and agonist-induced G protein 
activation and β-arrestin recruitment of CB1R, as well as to identify possible differences 
caused in these two main effector functions of the receptor. Interestingly, single alanine 
mutation of the conserved Arg (R3.50A) resulted only in a ~20% reduction of the G 
protein coupling efficiency of CB1R, without affecting its basal G protein activation. This 
may seem surprising, as crystal structure analysis as well as several mutational data have 
suggested a pivotal role for this residue in the G protein coupling of 7TMRs (Zhu et al. 
1994; Ballesteros et al. 1998; Rasmussen et al. 2011). However, several other 7TMRs 
exist, where similar non-conservative mutations of R3.50 failed to abolish G protein 
activation of the receptor (Fanelli et al. 1999; Rovati et al. 2007). Thus, CB1R appears to 
belong to a subgroup of 7TMRs where this conserved Arg residue plays no absolute role 
in the direct receptor-G protein coupling.  Furthermore, our results demonstrate a basal β-
arr2 recruitment of the CB1R-DAY mutant (or any double or triple mutant carrying the 
same mutation), which is in good accordance with previously published data showing 
similar characteristics for R3.50H mutants of V2 vasopressin, α1B adrenergic and AT1A 
angiotensin II receptors (Wilbanks et al. 2002). This strengthens the idea that this 
conserved Arg somehow prevents arrestin binding in the inactive receptor conformation. 
Agonist-induced β-arr2 recruitment of CB1R-DAY and CB1R-DRA was lowered, which 
is most likely to be caused by the lowered plasma membrane localization of these 
mutants (Fig. 1I). 
The most interesting finding of our study is the major difference between the functions of 

























R3.50A mutation, and accordingly show increased basal β-arr2 recruitment, their ultimate 
characteristics are further determined by the location of the second mutation. Thereby, a 
simultaneous lack of D3.49 and R3.50 residues seems to have a dominant-positive effect 
on both the β-arr1 and β-arr2 recruitment of CB1R (which is also supported by the fact 
that the triple mutant CB1R-AAA functionally resembles CB1R-AAY). Thus, CB1R-AAY 
is a β-arrestin-biased 7TMR mutant. Interestingly, these characteristics of the CB1R-AAY 
are similar to those of the formerly described biased mutant angiotensin II receptor AT1-
DRY/AAY (AT1R-AAY) (Gaborik et al. 2003; Wei et al. 2003). However, an important 
difference here is that AT1R-AAY is β-arrestin-biased in a way that its G protein 
activation is absent while its β-arrestin binding is present but certainly not increased (Wei 
et al. 2003, Balla et al., 2012), whereas CB1R-AAY is β-arrestin-biased in that its β-
arrestin recruitment is substantially increased, together with a lowered, but not abolished 
G protein activating ability. Furthermore, we were able to detect a robustly enhanced β-
arr1 recruitment to CB1R-AAY, whereas β-arr1 translocation to CB1R-WT was 
significant only upon 2-AG stimulus, but not after WIN55 treatment. Thus, it appears that 
the recruitment of β-arr1 to CB1R-WT is very weak, so that it challenges the limits of 
detectability via the (otherwise quite sensitive) BRET approach applied here. However, 
our results showing a significant increase of β-arr1 BRET upon 2-AG stimulus are in 
accordance with recent results showing higher β-arr1 recruitment by 2-AG compared to 
WIN55 (Laprairie et al., 2014). Taken together, recruitment of β-arr1 to CB1R-WT is 
obviously lower than that of β-arr2, but both are substantially enhanced in the CB1R-
AAY mutant. Interestingly, basal G protein activation of CB1R-AAY was absent, while 
the difference between vehicle-treated and WIN55-stimulated cells remained comparable 
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to that of CB1R-WT (Fig. 4A), raising the question whether the reduced Emax value of 
CB1R-AAY in this assay reflects a true loss of agonist-induced G protein activation, or it 
is caused merely by the absence of basal activity, while WIN55-induced G protein 
activation remains unaffected. However, repeating these experiments in HeLa cells, 
where basal activity of CB1R is minimal (Gyombolai et al. 2013), also showed 
substantially impaired WIN55-induced G protein activation of CB1R-AAY (Suppl. Fig. 
1), suggesting that this mutation reduces not only the basal but also the WIN55-induced 
























In contrast, CB1R-DAA proved to be G protein-biased, as its β-arrestin recruitment in 
response to agonist stimulus was practically absent, but was still able to activate G 
proteins, although at a lower level (~70% of the wild type CB1R). According to our data, 
plasma membrane expression of this mutant is ~40% lower than that of CB1R-WT. 
However, this extent of decrease is not likely to cause a complete loss of agonist-induced 
β-arrestin recruitment, given the ~1:1 stoichiometry of receptor-β-arrestin complex. This 
is also supported by the fact that CB1R-DAA still binds β-arr2 under basal conditions. 
Other 7TMRs described previously as biased mutants include the M3-R3.50L designer 
muscarinic receptor (Nakajima and Wess 2012) and β2-AR-TYY, a triple mutant β2-AR 
which was rationally designed to be functionally selective (Shenoy et al. 2006). 
Interestingly, however, all of these mutants are β-arrestin-biased, i.e. they do not couple 
to G proteins but still recruit β-arrestin, albeit at a lowered level. The CB1R-DAA mutant 
presented here is interesting in this respect, as it is biased towards G protein activation, 
whereas its mutations affect a ‘classical’ G protein-coupling region, i.e. the DRY motif. 

























stimulus, it still binds β-arr2 to some extent under non-stimulated conditions. This relies 
most probably on the presence of the R3.50A mutation, because, as mentioned above, all 
of the CB1R mutants carrying this mutation recruited β-arr2 constitutively. Thus, it seems 
that the absence of the conserved Arg residue can itself determine a receptor 
conformation that binds β-arrestin spontaneously. On the other hand, the agonist-induced 
β-arr2 binding of the receptor can still be strongly influenced in both directions by co-
mutations of the neighboring residues.  
Taken together, our results obtained with the CB1R-AAY and CB1R-DAA mutants 
strongly support a model where the active G protein-coupled and β-arrestin-bound 
conformations of a 7TMR are different. Moreover, receptor states responsible for 
constitutive and agonist-induced β-arrestin binding may also show differences. 
We also demonstrate here that the agonist-induced ERK1/2 phosphorylation shows good 
correlation with the β-arr2 recruitment of our biased CB1R mutants, rather than their G 
protein activation or their ability to inhibit forskolin-induced cAMP accumulation. These 
data are consistent with the recently emerging concept of β-arrestin-dependent CB1R 
signaling, i.e. a β-arrestin-mediated ERK1/2 phosphorylation following CB1R activation 
(Ahn et al. 2013a; Mahavadi et al. 2014). 
One of the most interesting questions regarding the DRY mutants presented here is how 
(i.e. through which molecular structural rearrangements) the distinct mutations induce 
such large differences in the β-arrestin-recruitment of CB1R. One simple explanation 
would be that mutations of the DRY motif modify primarily the G protein binding of the 
receptor, and their effects on the β-arr2 recruitment are merely secondary, resulting from 

























if this would be the only explanation, one should observe an indirect proportionality 
between the G protein-and the β-arrestin binding abilities of the distinct mutants, which is 
actually not the case. Thus, mutations of the DRY motif most probably affect β-arr2 
binding of CB1R independently of its G protein activation. Whether or not the DRY 
sequence itself is a part of the docking site for arrestins, can not be answered 
unequivocally based on our results. However, previously published data indicating that 
the ICL2 loop of 7TMRs, beginning with an intact DRY motif, is part of the β-arrestin 
binding site, add interesting aspects to our study (Huttenrauch et al. 2002; Marion et al. 
2006). Moreover, two recent studies have provided important insights into the structural 
features within the 7TMR-β-arrestin complex. Both of these studies point to an important 
interaction between the ‘finger loop’ region of β-arrestin and the receptor core, with the 
direct involvement of the DRY motif (Shukla et al., 2014; Szczepek et al., 2014). 
Combined with these data, our results show good fit with a model where DRY is directly 
involved in the β-arrestin binding of CB1R. Additionally, mutations of the DRY motif 
may also affect β-arrestin binding indirectly, i.e. by inducing structural rearrangements in 
the subsequent ICL2, resulting in diverse, sometimes completely opposite β-arrestin 
binding phenotypes.  However, a more precise understanding of the intramolecular 
interactions that mediate these characteristics would require the high resolution crystal 
structure data. 
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Fig.1 Cellular distribution of wild-type and mutant mVenus-tagged CB1R variants 
A-H, CHO cells expressing mVenus-tagged CB1R variants are visualized using confocal 
microscopy. A, CB1R-WT-mVenus B, CB1R-ARY-mVenus C, CB1R-DAY-mVenus, D, 
CB1R-DRA-mVenus E, CB1R-DAA-mVenus F, CB1R-ARA-mVenus G, CB1R-AAY-
mVenus H, CB1R-AAA-mVenus. Images are representative from 3 independent 
experiments. Scale bar 10 μm. I, PM/total receptor BRET showing the fraction of 
mVenus-tagged CB1R variants residing on the plasma membrane. 0% reflects no net 
BRET interaction and 100% reflects normalized BRET interaction of CB1R-WT-
mVenus. Data are mean±SEM, n=3, *p<0.05, ns – non-significant 
 
Fig.2 Functional analysis of the CB1R-DAY mutant 
A-B, Dose-response curves showing G protein activation of CB1R-WT (grey curve) and 
CB1R-DAY (black curve) in CHO cells under basal and different WIN55- (A) or 2-AG- 
(B) stimulated conditions, as detected by Go protein BRET. 0% reflects total inactivity of 
receptors, achieved by inverse agonist treatment (AM251, 10 μM), and 100% reflects 
maximal WIN55- (A) or 2-AG- (B) induced response (Emax) of CB1R-WT. Data are 
mean±SEM, n=3-8. 
C-H, Confocal images showing distribution of β-arr2-GFP in CHO cells co-expressing 
CB1R-WT (C and D) or CB1R-DAY (E-H), under control conditions (C, E and G) and 10 

























arr2-GFP puncta at the plasma membrane. Images are representative from at least 4 
independent experiments. Scale bar 10 μm. 
I-J, Dose-response curves showing recruitment of β-arr2 to the plasma membrane by 
CB1R-WT (grey curve) and CB1R-DAY (black curve) in CHO cells under basal and 
different WIN55- (I) or 2-AG- (J) stimulated conditions, as detected by BRET between β-
arr2-Rluc and MP-mVenus. 0% reflects total inactivity of receptors, achieved by inverse 
agonist treatment (AM251, 10 μM), and 100% reflects maximal WIN55- (I) or 2-AG- (J) 
induced response (Emax) of CB1R-WT. Data are mean±SEM, n=4-7. 
 
Fig.3 Functional analysis of the CB1R-DRA mutant 
A-B, Dose-response curves showing G protein activation of CB1R-WT (grey curve) and 
CB1R-DRA (black curve) in CHO cells under basal and different WIN55- (A) or 2-AG- 
(B) stimulated conditions, as detected by Go protein BRET. 0% reflects total inactivity of 
receptors, achieved by inverse agonist treatment (AM251, 10 μM), and 100% reflects 
maximal WIN55- (A) or 2-AG- (B) induced response (Emax) of CB1R-WT. Data are 
mean±SEM, n=4-8. 
C-F, Confocal images showing distribution of β-arr2-GFP in CHO cells co-expressing 
CB1R-DRA, under control conditions (C and E) and 10 min after WIN55 (1 μM, D) or 
AM251 (10 μM, F) treatment. Arrows indicate β-arr2-GFP puncta at the plasma 
membrane. Images are representative from at least 4 independent experiments. Scale bar 
10 μm. 
G-H, Dose-response curves showing recruitment of β-arr2 to the plasma membrane by 

























different WIN55- (G) or 2-AG- (H) stimulated conditions, as detected by BRET between 
β-arr2-Rluc and MP-mVenus. 0% reflects total inactivity of receptors, achieved by 
inverse agonist treatment (AM251, 10 μM), and 100% reflects maximal WIN55- (G) or 
2-AG- (H) induced response (Emax) of CB1R-WT. Data are mean±SEM, n=4-7. 
 
Fig.4 Functional analysis of the CB1R-AAY mutant 
A-B, Dose-response curves showing G protein activation of CB1R-WT (grey curve) and 
CB1R-AAY (black curve) in CHO cells under basal and different WIN55- (A) or 2-AG- 
(B) stimulated conditions, as detected by Go protein BRET. 0% reflects total inactivity of 
receptors, achieved by inverse agonist treatment (AM251, 10 μM), and 100% reflects 
maximal WIN55- (A) or 2-AG- (B) induced response (Emax) of CB1R-WT. Data are 
mean±SEM, n=3-8. 
C-F, Confocal images showing distribution of β-arr2-GFP in CHO cells co-expressing 
CB1R-AAY, under control conditions (C and E) and 10 min after WIN55 (1 μM, D) or 
AM251 (10 μM, F) treatment. Images are representative from at least 3 independent 
experiments. Scale bar 10 μm. 
G-H, Dose-response curves showing recruitment of β-arr2 to the plasma membrane by 
CB1R-WT (grey curve) and CB1R-AAY (black curve) in CHO cells under basal and 
different WIN55- (G) or 2-AG- (H) stimulated conditions, as detected by BRET between 
β-arr2-Rluc and MP-mVenus. 0% reflects total inactivity of receptors, achieved by 
inverse agonist treatment (AM251, 10 μM), and 100% reflects maximal WIN55- (G) or 
2-AG- (H) induced response (Emax) of CB1R-WT. Data are mean±SEM, n=4-7. 
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A-B, Dose-response curves showing G protein activation of CB1R-WT (grey curve) and 
CB1R-DAA (black curve) in CHO cells under basal and different WIN55- (A) or 2-AG- 
(B) stimulated conditions, as detected by Go protein BRET. 0% reflects total inactivity of 
receptors, achieved by inverse agonist treatment (AM251, 10 μM), and 100% reflects 
maximal WIN55- (A) or 2-AG- (B) induced response (Emax) of CB1R-WT. Data are 
mean±SEM, n=4-8. 
C-F, Confocal images showing distribution of β-arr2-GFP in CHO cells co-expressing 
CB1R-DAA, under control conditions (C and E) and 10 min after WIN55 (1 μM, D) or 
AM251 (10 μM, F) treatment. Images are representative from at least 3 independent 
experiments. Scale bar 10 μm. 
G-H, Dose-response curves showing recruitment of β-arr2 to the plasma membrane by 
CB1R-WT (grey curve) and CB1R-DAA (black triangles) in CHO cells under basal and 
different WIN55- (G) or 2-AG- (H) stimulated conditions, as detected by BRET between 
β-arr2-Rluc and MP-mVenus. 0% reflects total inactivity of receptors, achieved by 
inverse agonist treatment (AM251, 10 μM), and 100% reflects maximal WIN55- (G) or 
2-AG- (H) induced response (Emax) of CB1R-WT. Data are mean±SEM, n=4-7. 
 
Fig.6 Dose-response curves showing β-arrestin1 recruitment of CB1R mutants 
A-B, Dose-response curves showing recruitment of β-arr1 to the plasma membrane by 
CB1R-WT (black circles), CB1R-DAY (white diamonds), CB1R-DRA (white circles), 
CB1R-DAA (white squares) or CB1R-AAY (white triangles) in CHO cells under basal 

























between β-arr1-Rluc and MP-mVenus. 0% reflects total inactivity of receptors, achieved 
by inverse agonist treatment (AM251, 10 μM), and 100% reflects maximal WIN55- (A) 
or 2-AG- (B) induced response (Emax) of CB1R-AAY. Data are mean±SEM, n=3. 
*p<0.05 vs vehicle treatment. 
 
Fig.7 Bias analysis showing functional selectivity of CB1R mutants 
A-B, Equimolar comparison of CB1R-WT (black points), CB1R-DAA (grey squares) and 
CB1R-AAY (white triangles) functions. For each receptor, responses from G protein and 
β-arr2 BRET dose-response curves, elicited by the same WIN55 (A) or 2-AG (B) 
concentration, were plotted against each other. The left- and upward shift of CB1R-AAY 
points represents bias toward β-arr2 recruitment, whereas the downward shift of CB1R-
DAA points indicates G protein bias. Data are mean±SEM. C, Equiactive comparison of 
CB1R-WT, CB1R-DAA and CB1R-AAY functions. The biased factor (β) was calculated 
for each receptor, based upon EC50 and Emax values of G protein and β-arr2 BRET dose-
response curves obtained with WIN55 (black bars) or 2-AG (grey bars) stimuli, using the 
equation described in Materials and methods. CB1R-WT was used as reference receptor. 
Positive values indicate bias towards G protein signaling, whereas negative values reflect 
β-arrestin bias. Data are mean ± SD. 
 
Fig.8 Functional assays measuring intracellular signaling of wild-type and mutant 
CB1R variants  
A, Dose-response curves showing the inhibition of forskolin-induced cAMP 

























basal and different WIN55-stimulated conditions, measured by the BRET changes of an 
EPAC-based intramolecular BRET sensor. BRET was measured 30 min after stimulus. 
0% reflects total inactivity of receptors, achieved by inverse agonist treatment (AM251, 
10 μM), and 100% reflects maximal WIN55-induced response (Emax) of CB1R-WT. Data 
are mean±SEM, n=6. *p<0.05 vs basal state, #p<0.05 vs CB1R-WT. B, Amounts of 
phosphorylated (pERK1/2) and total ERK1/2 proteins detected by Western blot in CHO 
cells expressing CB1R-WT, CB1R-DAA or CB1R-AAY, after 0, 5 or 20 min of WIN55 (1 
μM) treatment. Images are representative from four independent experiments. C, 
Quantification of Western blot data. 0% reflects background intensity, and 100% reflects 
WIN55-induced pERK1/2 intensity of CB1R-WT at 5 min. Data are mean+SEM, n=4, 
*p<0.05 versus CB1R-WT at 5 min,  #p<0.05 versus CB1R-WT at 20 min. 
 
Supplementary Fig. 1  G protein activation of CB1R-AAY mutant in HeLa cells 
BRET measurements showing Go protein activation of CB1R-WT and CB1R-AAY in 
HeLa cells under basal (white bars) and WIN55-stimulated (1 μM, black bars) conditions. 
0% reflects total inactivity of receptors, achieved by inverse agonist treatment (AM251, 
10 μM), and 100% reflects WIN55-induced response of CB1R-WT. Data are mean±SEM, 
n=4. *p<0.05 vs basal, #p<0.05 vs CB1R-WT. 
 
Table 1. Parameters of Go BRET and β-arrestin2 BRET dose-response curves for 
the different CB1R variants 
Bottom and Emax values are expressed as % of Emax of CB1R-WT. Data are mean±SEM, 
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 Go BRET 
 WIN55 2-AG 
Receptor pEC50 bottom Emax pEC50 bottom Emax 
CB1R-WT -7.89±0.07 36.85±2.47 100 -7.43±0.07 50.11±2.18 100 
CB1R-DAY -7.85±0.17 37.19±3.95 83.12±3.95* -7.36±0.34 42.11±6.35 78.31±4.10* 
CB1R-DRA -6.78±0.27* 65.58±2.62* 97.22±4.31 -7.49±0.18 63.90±2.28* 87.49±1.35* 
CB1R-DAA -7.25±0.23 43.62±2.86 75.45±2.92* -7.26±0.39 53.99±3.56 72.79±2.48* 
CB1R-AAY -7.24±0.17* 0.36±4.24* 64.06±4.43* -6.95±0.15* 17.12±4.02* 77.69±3.52* 
 β-arr2 BRET 
 WIN55 2-AG 
Receptor pEC50 bottom Emax pEC50 bottom Emax 
CB1R-WT -6.80±0.051 1.23±2.53 100 -5.47±0.02 1.79±0.87 100 
CB1R-DAY -7.53±0.19* 25.13±3.77* 62.36±2.60* -6.65±0.28* 17.15±3.64* 44.72±2.71* 
CB1R-DRA -7.21±0.16* 14.43±2.09* 43.46±1.84* -6.41±0.16* 10.47±1.69* 35.22±1.52* 
CB1R-DAA > -5.0* 20.96±2.35* n.d. > -4.5* 14.62±5.10* n.d. 
CB1R-AAY -7.17±0.10* 32.68±10.90* 284.10±9.93* -6.24±0.14* 25.91±6.44* 145.30±6.74*
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